Upcoming event

Clinical evaluation and disease management of PI-RADS 3 lesions. Analysis from a single tertiary high-volume center

  • Ettore Di Trapani 1,
  • Gennaro Musi 1,
  • Matteo Ferro 1,
  • Giovanni Cordima 1,
  • Francesco Alessandro Mistretta 1,
  • Stefano Luzzago 1,
  • Roberto Bianchi 1,
  • Gabriele Cozzi 1,
  • Sarah Alessi 2,
  • Michele Catellani 1,
  • Deliu Victor Matei 1,
  • Barbara Alicja Jereczek-Fossa 3,
  • Giuseppe Petralia 2,
  • Ottavio De Cobelli 1
1 Division of Urology, European Institute of Oncology, IRCCS, Milan, Italy 2 Precision Imaging and Research Unit, Department of Medical Imaging and Radiation Sciences, European Institute of Oncology, IRCCS, Milan, Italy 3 Division of Radiation Oncology, European Institute of Oncology, IRCCS, Milan, Italy

Publication: Scandinavian Journal of Urology, August 2020


To evaluate the clinical and pathological implications of Prostate Cancer (PCa) patients with a Prostate Imaging – Reporting and Data System (PI-RADS) 3 lesion at multi parametric magnetic resonance imaging (mpMRI).


We included 356 patients with a PI-RADS score 3 lesion at mpMRI who underwent prostate biopsy for a suspect of PCa at a single tertiary high-volume centre between 2013 and 2016.
We developed Uni- (UVA) and multi variable (MVA) logistic regression analyses assessing the predictors of three endpoints: 1) diagnosis of PCa, 2) active surveillance (AS) criteria and 3) clinically significant (CS) PCa at final pathology.


PCa was diagnosed in 285 patients (80%), out of these 154 (56%) were eligible for AS according to Prostate Cancer Research International Active Surveillance (PRIAS) criteria. Over the 228 (64%) patients who underwent surgery, 93 (40.8%) had a CS disease at final pathology. Hundred and ninety-three (84.6%) had a pT2 disease and 35 (15.4%) had a pT3 disease. The size of the main lesion, age, PSA and prostate volume efficiently predicted PCa at MVA (all p < 0.05). None of our predictors were significantly associated with AS characteristics. Over those patients who underwent surgery, the biopsy Gleason Score (p = 0.007) efficiently predicted a CS PCa at final pathology.


mpMRI-detected PI-RADS 3 lesions should be sent to a prostate biopsy if other clinical parameters suggest the presence of a PCa. In case of diagnosis of a PCa, patients should undergo confirmatory biopsy before being included in AS protocols to avoid underestimation of a CS disease.